UB Paderborn / Katalog / Suche / in CDI

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

Neurology, 2011-05, Vol.76 (22), p.1858

2011

Link zum Volltext

Verfügbarkeit prüfen

Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures

Multiple sclerosis, 2012-08, Vol.18 (8), p.1074-1080

2012

Link zum Volltext

Verfügbarkeit prüfen

Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire

Multiple sclerosis, 2008-08, Vol.14 (7), p.940-946

2008

Link zum Volltext

Verfügbarkeit prüfen

The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

Multiple sclerosis, 1999-08, Vol.5 (4), p.244-250

1999

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

Multiple sclerosis, 2010-11, Vol.16 (11), p.1385-1392

2010

Link zum Volltext

Verfügbarkeit prüfen

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS

Neurology, 2001-10, Vol.57 (7), p.1239

2001

Link zum Volltext

Verfügbarkeit prüfen

Eight-year follow-up study of brain atrophy in patients with MS

Neurology, 2002-11, Vol.59 (9), p.1412

2002

Link zum Volltext

Verfügbarkeit prüfen

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis

Neurology, 2005-03, Vol.64 (6), p.992

2005

Link zum Volltext

Verfügbarkeit prüfen

Axonal loss in normal-appearing white matter in a patient with acute MS

Neurology, 2001-10, Vol.57 (7), p.1248

2001

Link zum Volltext

Verfügbarkeit prüfen

Assessing disability progression with the Multiple Sclerosis Functional Composite

Multiple sclerosis, 2009-08, Vol.15 (8), p.984-997

2009

Link zum Volltext

Verfügbarkeit prüfen

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

Multiple sclerosis, 2002-10, Vol.8 (5), p.359-365

2002

Link zum Volltext

Verfügbarkeit prüfen

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study

Multiple sclerosis, 2010-05, Vol.16 (5), p.588-596

2010

Link zum Volltext

Verfügbarkeit prüfen

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

Neurology, 2007-04, Vol.68 (16), p.1299

2007

Link zum Volltext

Verfügbarkeit prüfen

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a

Neurology, 2009-06, Vol.72 (23), p.1989

2009

Link zum Volltext

Verfügbarkeit prüfen

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

Brain (London, England : 1878), 1999-05, Vol.122 (5), p.871-882

1999

Link zum Volltext

Verfügbarkeit prüfen

T‐cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking

Clinical and experimental immunology, 2002-09, Vol.129 (3), p.510-518

2002

Link zum Volltext

Verfügbarkeit prüfen

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

Neurology, 1998-05, Vol.50 (5), p.1294

1998

Link zum Volltext

Verfügbarkeit prüfen

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS

Neurology, 2001-05, Vol.56 (10), p.1324

2001

Link zum Volltext

Verfügbarkeit prüfen

Management of Multiple Sclerosis

The New England journal of medicine, 1997-11, Vol.337 (22), p.1604-1611

1997

Link zum Volltext

Verfügbarkeit prüfen

Multiple Sclerosis Performance Test: validation of self‐administered neuroperformance modules

European journal of neurology, 2020-05, Vol.27 (5), p.878-886

2020

Link zum Volltext

Verfügbarkeit prüfen

Optimal reference population for the multiple sclerosis functional composite

Multiple sclerosis, 2007-08, Vol.13 (7), p.909-914

2007

Link zum Volltext

Verfügbarkeit prüfen

Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury

Multiple sclerosis, 2008-09, Vol.14 (8), p.1036-1043

2008

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

Journal of neurology, 2009-03, Vol.256 (3), p.405-415

2009

Link zum Volltext

Verfügbarkeit prüfen

Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis

European journal of neurology, 2005-07, Vol.12 (7), p.550-556

2005

Link zum Volltext

Verfügbarkeit prüfen

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

Multiple sclerosis, 2000-12, Vol.6 (6), p.373-377

2000

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures

Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire

The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS

Eight-year follow-up study of brain atrophy in patients with MS

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis

Axonal loss in normal-appearing white matter in a patient with acute MS

Assessing disability progression with the Multiple Sclerosis Functional Composite

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

T‐cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS

Management of Multiple Sclerosis

Multiple Sclerosis Performance Test: validation of self‐administered neuroperformance modules

Optimal reference population for the multiple sclerosis functional composite

Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

Suchergebnisse filtern